Compounds of the general formula (I) wherein R 1 and R 2 are identical or different and represent, each independently of each other, a hydrogen atom or a linear or branched, cyclic or cyclic branched, saturated or unsaturated C 1 -C p alkyl group, which can be substituted with one or more substituents selected from the group comprising: -OR 3 , -NR 3 R 4 , -NO 2 , -COR 3 , -COOR 3 , -CF 3 , -CR 3 F 2 , -CR 3 R 4 F, =O, -CN, halogen, -SR 3 , -SO 2 R 3 and aryl, with - p is an integer between 2 and 18, - R 3 and R 4 are identical or different and represent, each independently of each other, - either a group selected from the group comprising: -H, -OH, -NH 2 , -NO 2 , -COOH, -CF 3 , -CHF 2 , -CH 2 F, =O, -CN, halogen, -SH and -SO 2 H, - or a linear or branched, cyclic or cyclic branched, saturated or unsaturated C 1 -C 6 alkyl group, which can be substituted with one or more substituents selected from the group comprising: -H, -OH, -NH 2 , -NO 2 , -COOH, -CF 3 , -CHF 2 , -CH 2 F, =0, -CN, halogen, -SH and -SO 2 H, Q 1 , Q 2 , Q 3 and Q 4 represent, each independently of each other, a radical selected from the group comprising: a cafeoyl group, a CH 3 -CH(OH)-CH 2 -CO- group and a hydrogen atom, with the proviso that at least one of these radicals is a cafeoyl group, stereoisomers thereof and pharmaceutically or nutraceutically acceptable salts thereof, for their use in preventing and/or treating a neurodegenerative disease. R 1 and R 2 are identical or different and represent, each independently of each other, a hydrogen atom or a linear or branched, cyclic or cyclic branched, saturated or unsaturated C 1 -C p alkyl group, which can be substituted with one or more substituents selected from the group comprising: -OR 3 , -NR 3 R 4 , -NO 2 , -COR 3 , -COOR 3 , -CF 3 , -CR 3 F 2 , -CR 3 R 4 F, =O, -CN, halogen, -SR 3 , -SO 2 R 3 and aryl, with - p is an integer between 2 and 18, - R 3 and R 4 are identical or different and represent, each independently of each other, - either a group selected from the group comprising: -H, -OH, -NH 2 , -NO 2 , -COOH, -CF 3 , -CHF 2 , -CH 2 F, =O, -CN, halogen, -SH and -SO 2 H, - or a linear or branched, cyclic or cyclic branched, saturated or unsaturated C 1 -C 6 alkyl group, which can be substituted with one or more substituents selected from the group comprising: -H, -OH, -NH 2 , -NO 2 , -COOH, -CF 3 , -CHF 2 , -CH 2 F, =0, -CN, halogen, -SH and -SO 2 H, - p is an integer between 2 and 18, - R 3 and R 4 are identical or different and represent, each independently of each other, - either a group selected from the group comprising: -H, -OH, -NH 2 , -NO 2 , -COOH, -CF 3 , -CHF 2 , -CH 2 F, =O, -CN, halogen, -SH and -SO 2 H, - or a linear or branched, cyclic or cyclic branched, saturated or unsaturated C 1 -C 6 alkyl group, which can be substituted with one or more substituents selected from the group comprising: -H, -OH, -NH 2 , -NO 2 , -COOH, -CF 3 , -CHF 2 , -CH 2 F, =0, -CN, halogen, -SH and -SO 2 H, Q 1 , Q 2 , Q 3 and Q 4 represent, each independently of each other, a radical selected from the group comprising: a cafeoyl group, a CH 3 -CH(OH)-CH 2 -CO- group and a hydrogen atom, with the proviso that at least one of these radicals is a cafeoyl group, stereoisomers thereof and pharmaceutically or nutraceutically acceptable salts thereof, for their use in preventing and/or treating a neurodegenerative disease. a cafeoyl group, a CH 3 -CH(OH)-CH 2 -CO- group and a hydrogen atom, with the proviso that at least one of these radicals is a cafeoyl group, stereoisomers thereof and pharmaceutically or nutraceutically acceptable salts thereof, for their use in preventing and/or treating a neurodegenerative disease. <EOS>